CD19-CAR-T Cells in Patients With R/R B-ALL

Summary

This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of autologous or donor-derived allogeneic T cells expressing CD19 chimeric antigen receptors (referred to as "CD19-CAR-T cells") in patients with relapsed or refractory acute B-cell lymphoblastic leukemia (R/R B-ALL).

Timeline

Start

2018-07-20

Primary completion

2019-12-31

Completion

2019-12-31

Drugs

Indications